Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
09 2022
Historique:
received: 20 05 2022
revised: 27 07 2022
accepted: 11 08 2022
pubmed: 5 9 2022
medline: 14 9 2022
entrez: 4 9 2022
Statut: ppublish

Résumé

NAFLD is currently considered the most common liver disease worldwide and mounting data support its strong link with atherosclerotic cardiovascular disease (ASCVD). This association is important as cardiovascular disease (CVD) is generally recognized as the leading cause of death in individuals with NAFLD. However, NAFLD represents a heterogeneous condition showing a wide spectrum of clinical and pathophysiological sub-phenotypes with different adverse outcomes ranging from ASCVD to liver damage progression. The contribution to NAFLD pathogenesis of different environmental, metabolic, and genetic factors underlies this heterogeneity. The more frequent phenotype of NAFLD patients is associated with metabolic dysfunctions such as obesity and insulin-resistant syndrome and this has been recently named as Metabolic Associated Fatty Liver disease (MAFLD). However, NAFLD is encountered also in subjects without insulin resistance and metabolic alterations and in whom genetic factors play a major role. It has been suggested that these individuals are at risk of liver disease progression but not of cardiovascular complications. Separating metabolic from genetic factors could be useful in disentangling the intricate relationship between NAFLD and atherosclerosis. In the present review, we aim to address the epidemic of NAFLD, its epidemiologically association with ASCVD complications and the overall mechanisms involved in the pathophysiology of atherosclerotic vascular damage in NAFLD patients. Finally, we will revise the potential role of genetics in identifying disease subtyping and predicting individualised CVD risk.

Identifiants

pubmed: 36058083
pii: S0021-9150(22)01394-6
doi: 10.1016/j.atherosclerosis.2022.08.011
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-59

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Francesco Baratta (F)

Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.

Laura D'Erasmo (L)

Department of Translational and Precision Medicine, Sapienza University of Rome, 00161, Rome, Italy.

Simone Bini (S)

Department of Translational and Precision Medicine, Sapienza University of Rome, 00161, Rome, Italy.

Daniele Pastori (D)

Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.

Francesco Angelico (F)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161, Rome, Italy.

Maria Del Ben (M)

Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.

Marcello Arca (M)

Department of Translational and Precision Medicine, Sapienza University of Rome, 00161, Rome, Italy.

Alessia Di Costanzo (A)

Department of Translational and Precision Medicine, Sapienza University of Rome, 00161, Rome, Italy. Electronic address: alessia.dicostanzo@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH